Results 121 to 130 of about 5,144 (141)

Ixekizumab

Reactions Weekly, 2021
  +6 more sources

Ixekizumab

Reactions Weekly, 2023
  +5 more sources

Disease response and patient-reported outcomes among initiators of ixekizumab

Journal of Dermatological Treatment, 2022
Russel T Burge, Mona Shahriari, Mwangi J Murage   +2 more
exaly  

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

Clinical Rheumatology, 2022
Atul Deodhar, Peter Nash, Laura C. Coates   +2 more
exaly  

Ixekizumab

Reactions Weekly, 2018
openaire   +2 more sources

Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry

Dermatologic Therapy, 2021
Russel T Burge, Bruce E Strober
exaly  

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Lancet, The, 2020
Walter P Maksymowych, Atul Deodhar, Tae-Hwan Kim   +2 more
exaly  

Ixekizumab

2016
Shivani P. Reddy, Vidhi V. Shah, Jashin J. Wu   +2 more
openaire   +1 more source

Journal of Dermatological Treatment

Journal of Dermatological Treatment, 2023
Ennio Lubrano Di Scorpaniello, Adam Reich, Catherine Reed   +2 more
exaly  

Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events

Journal of Dermatological Treatment, 2022
Russel T Burge, Rebecca Power, Susanne R Gulliver   +2 more
exaly